Tricida, Inc.
NASDAQ: TCDA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gerrit Klaerner
- Employees
- 57
- Headquarters
- South San Francisco, United States
- IPO year
- 2018
- Market cap
- $6.0M
- Website
- https://www.tricida.com
Loading TCDA…
Loading profile data…Frequently asked questions about TCDA
What does Tricida, Inc. (TCDA) do?
Tricida, Inc. operates as a biopharmaceutical firm with a primary focus on the advancement and market introduction of veverimer (TRC101). This compound, an orally ingested, non-systemic polymer, has successfully concluded its Phase III clinical trials. Veverimer is designed to address metabolic acidosis in individuals suffering from chronic kidn...
Where does TCDA trade?
Tricida, Inc. (TCDA) trades on the NASDAQ Global Select.
What sector is TCDA in?
Tricida, Inc. (TCDA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Tricida, Inc.?
Gerrit Klaerner is the chief executive officer of Tricida, Inc. (TCDA).
Where is Tricida, Inc. headquartered?
Tricida, Inc. is headquartered in United States.
Does TCDA pay a dividend?
Tricida, Inc. (TCDA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TCDA go public?
Tricida, Inc. (TCDA) completed its initial public offering in 2018.